[
  {
    "ts": "2026-01-20T11:00:00+00:00",
    "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
    "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
    "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "449ac09a-53b1-3b8e-bd31-18eb9785f02a",
      "content": {
        "id": "449ac09a-53b1-3b8e-bd31-18eb9785f02a",
        "contentType": "STORY",
        "title": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
        "description": "",
        "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
        "pubDate": "2026-01-20T11:00:00Z",
        "displayTime": "2026-01-20T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-merck-announce-5-data-110000479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]